☆ 4.7 Article

Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 41, Issue 16_suppl, Pages 7506-7506

Publisher

American Society of Clinical Oncology (ASCO)

DOI: 10.1200/jco.2023.41.16_suppl.7506

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.